Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics issues business update for the third-quarter of 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Mechanical force switches T cell from disease-scanning to disease-fighting mode

Mechanical force switches T cell from disease-scanning to disease-fighting mode

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Scientists report a major step forward in the development of an effective therapy against Nipah virus

Scientists report a major step forward in the development of an effective therapy against Nipah virus

Four abstracts on RSV and influenza prevention in pediatric health to be presented

Four abstracts on RSV and influenza prevention in pediatric health to be presented

iCo Therapeutics announces $4,000,000 brokered private placement

iCo Therapeutics announces $4,000,000 brokered private placement

Immunotherapy, a new therapeutic area to destroy tumor cells

Immunotherapy, a new therapeutic area to destroy tumor cells

Research suggests the possibility of an effective treatment for Hendra virus infections in humans

Research suggests the possibility of an effective treatment for Hendra virus infections in humans

sanofi-aventis reports financial results for the third quarter of 2009

sanofi-aventis reports financial results for the third quarter of 2009

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Drug delivery device companies need to rethink their strategies to remain competitive

Drug delivery device companies need to rethink their strategies to remain competitive

European Patent Office to grant patent for R&D Antibodies’ immunoassays and apparatuses

European Patent Office to grant patent for R&D Antibodies’ immunoassays and apparatuses

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Recruitment of Phase II trial of TB-402 completed ahead of schedule

Recruitment of Phase II trial of TB-402 completed ahead of schedule

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.